Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICON, Advarra partnership aims to optimize trials, expand access
ICON and Advarra have partnered to create a connected network of clinical trial sites that integrates ICON’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
ICON partners with Advarra to launch connected site network model
ICON and Advarra have formed a partnership to create a connected, research ready site network that integrates ICON’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
ICON, Advarra partner on connected site network model
ICON plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Beyond viral suppression: Next-generation HIV therapeutics target reservoirs, broadly neutralising antibodies, and gene editing
Long-acting injectables have transformed HIV management, but viral suppression alone is not enough. Researchers are advancing mRNA vaccines, broadly neutralizing antibodies, latency-reversing agents, pediatric immune strategies, and gene editing to eliminate reservoirs and achieve remission. Here’s how next-generation HIV therapeutics aim to move beyond lifelong ART.
-
When ambition meets ambiguity: The trends and sentiments shaping biotech in 2026
Deepali Suri, President ICON Biotech, provides insights into what biotech leaders anticipate in the coming two years, the therapies and modalities they’re focused on now and what macro and micro factors are impacting their operations.
-
China biotech continues its growth trajectory
Yao Zhong, vice president general manager for ICON China Mainland and Hong Kong, discusses latest survey results on the Chinese biotech market.
-
Mission (im)possible? Efficient Global Antibody Drug Conjugate Product Approvals
Antibody-drug conjugates (ADCs) continue to reshape global oncology, yet navigating the evolving regulatory landscape remains a significant challenge. In this latest ICON Regulatory Affairs article we outline the strategic considerations essential for efficient global development. See page 42.
-
From uncertainty to strategy: Guiding vaccine decisions in rare autoimmune conditions
Rare autoimmune diseases can increase patients’ vulnerability to infection and often require tailored considerations for vaccination. Read the article to learn what makes these cases distinct and what to factor in when designing a vaccine schedule.
-
The Bayesian challenge: complexity that pays off
ICON's Andrew Garrett and Tim Clark discuss the recent FDA draft guidance on how sponsors can use Bayesian models for clinical trials.
-
Flexible formulation strategies boost early phase clinical success
Early phase clinical success relies on simple, flexible formulations that can adapt to wide dose ranges, support matching placebos, and deliver reliable stability. This article explores how formulation strategies enable dose escalation, maintain blinding integrity, and streamline development in first‑in‑human trials. It also highlights practical considerations for selecting dosage forms and designing stability programs that balance speed, cost, and clinical needs.
